RVMD vs. SMMT: Revolution Medicines vs. Summit Therapeutics Stock Comparison
How do Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | RVMD | SMMT |
|---|---|---|
| Name | Revolution Medicines, Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 41.59 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | February 13, 2020 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| Total Return (1Y) | 224.80% | -2.48% |
| Total Return (3Y, Annualized) | 114.71% | 116.18% |
| Total Return (5Y, Annualized) | 43.47% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Revolution Medicines (RVMD) has a non-negative beta of 1.42.
| Metric | RVMD | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 68.29% | 75.06% |
| Beta (5Y) | 1.42 | -1.51 |
| Max Drawdown (5Y) | -55.71% | -87.64% |
| Avg. Volume (3M) | 2.06M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 3.23 | -0.09 |
| Sortino Ratio (1Y) | 6.92 | -0.13 |
Profitability
ROE (TTM)
Both Revolution Medicines (RVMD) at -93.56% and Summit Therapeutics (SMMT) at -220.01% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-93.56%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- RVMD
- -93.56%
- Min
- -167.77%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
Both Revolution Medicines (RVMD) at 0.00% and Summit Therapeutics (SMMT) at 0.00% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- RVMD
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-188.88%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- RVMD
- -188.88%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| ROE (TTM) | -93.56% | -220.01% |
| ROA (TTM) | -32.13% | -111.99% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -188.88% | 0.00% |
| Gross Margin (TTM) | 0.00% | 0.00% |
Growth
Revenue Growth
Neither Revolution Medicines (RVMD) nor Summit Therapeutics (SMMT) reports a revenue growth value for this period, so a direct comparison isn't possible.
EPS Growth
Neither Revolution Medicines (RVMD) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| Revenue Growth (YoY) | -- | -- |
| Revenue Growth (3Y CAGR) | -- | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Revolution Medicines (RVMD) at 8.36 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.36
- Max
- 25.13
- Q3
- 12.13
- RVMD
- 8.36
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Revolution Medicines (RVMD) at 0.50 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.50
- Max
- 1.42
- Q3
- 0.65
- RVMD
- 0.50
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 8.36 | 5.99 |
| Debt / Equity (MRQ) | 0.50 | 0.04 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Revolution Medicines (RVMD) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Revolution Medicines (RVMD) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RVMD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Revolution Medicines (RVMD) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RVMD
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for Revolution Medicines (RVMD), whose P/S ratio of 210.51 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
210.51
- RVMD
- 210.51
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
Measured against book value, both Revolution Medicines (RVMD) at 17.31 and Summit Therapeutics (SMMT) at 23.13 look expensive — each P/B ratio sits above its industry’s benchmark range.
RVMD
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.31
- RVMD
- 17.31
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | RVMD | SMMT |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 210.51 | -- |
| P/B Ratio (MRQ) | 17.31 | 23.13 |
| Free Cash Flow Yield (TTM) | -2.13% | -1.64% |